Key facts
- This page summarizes Brian Goff's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
- 11 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2026, 16:17.
Brian Goff - 01 Mar 2026 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- AGIO
- Reported as of
- 01 Mar 2026
- Net transaction value
- -$522,873
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2026, 16:17:52 UTC
- Prior SEC filing
- 02 Jan 2026
- Next SEC filing
- 06 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Cook, as Attorney in Fact for Brian Goff
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian Goff filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 03 Mar 2026.
Change
- Previous filing in this sequence was filed on 02 Jan 2026.
- Current net transaction value: -$522,873.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001546216
Primary reporting owner
Goff Brian
- Relationship
- Chief Executive Officer, Director
- Address
- C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE
- Signature
- /s/ William Cook, as Attorney in Fact for Brian Goff
- Signature date
- 03 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGIO
transaction
Common stock
Options Exercise
- Transaction value
- $0
- Shares
- +8,500
- Change %
- +5.9%
- Price
- $0.000000
- Shares after
- 151,603
- Date
- 02 Mar 2026
- Ownership
- Direct
AGIO
transaction
Common stock
Sale
- Transaction value
- $112,075
- Shares
- -3,870
- Change %
- -2.6%
- Price
- $28.96
- Shares after
- 147,733
- Date
- 02 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
AGIO
transaction
Common stock
Options Exercise
- Transaction value
- $0
- Shares
- +18,000
- Change %
- +12%
- Price
- $0.000000
- Shares after
- 165,733
- Date
- 02 Mar 2026
- Ownership
- Direct
AGIO
transaction
Common stock
Sale
- Transaction value
- $239,412
- Shares
- -8,267
- Change %
- -5%
- Price
- $28.96
- Shares after
- 157,466
- Date
- 02 Mar 2026
- Ownership
- Direct
- Footnotes
- F2
AGIO
transaction
Common stock
Options Exercise
- Transaction value
- $0
- Shares
- +13,000
- Change %
- +8.3%
- Price
- $0.000000
- Shares after
- 170,466
- Date
- 02 Mar 2026
- Ownership
- Direct
AGIO
transaction
Common stock
Sale
- Transaction value
- $171,385
- Shares
- -5,918
- Change %
- -3.5%
- Price
- $28.96
- Shares after
- 164,548
- Date
- 02 Mar 2026
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGIO
transaction
Derivative
Restricted stock units
Award
- Transaction value
- $0
- Shares
- +48,000
- Change %
- Price
- $0.000000
- Shares after
- 48,000
- Date
- 01 Mar 2026
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 48,000
- Exercise price
- Footnotes
- F4, F5
AGIO
transaction
Derivative
Stock options (right to buy)
Award
- Transaction value
- $0
- Shares
- +174,000
- Change %
- Price
- $0.000000
- Shares after
- 174,000
- Date
- 01 Mar 2026
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 174,000
- Exercise price
- $30.23
- Footnotes
- F6
AGIO
transaction
Derivative
Restricted stock units
Options Exercise
- Transaction value
- $0
- Shares
- -8,500
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 02 Mar 2026
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 8,500
- Exercise price
- Footnotes
- F4, F7
AGIO
transaction
Derivative
Restricted stock units
Options Exercise
- Transaction value
- $0
- Shares
- -18,000
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 18,000
- Date
- 02 Mar 2026
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 18,000
- Exercise price
- Footnotes
- F4, F8
AGIO
transaction
Derivative
Restricted stock units
Options Exercise
- Transaction value
- $0
- Shares
- -13,000
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 26,000
- Date
- 02 Mar 2026
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 13,000
- Exercise price
- Footnotes
- F4, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 9 footnotes
Footnote F1
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
Footnote F2
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2024.
Footnote F3
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2025.
Footnote F4
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Footnote F5
The restricted stock units were granted on March 1, 2026. Beginning on March 1, 2027, the shares underlying the restricted stock units will vest in three equal annual installments.
Footnote F6
This option was granted on March 1, 2026. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Footnote F7
The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
Footnote F8
The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
Footnote F9
The restricted stock units were granted on March 1, 2025. Beginning on March 1, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.